Almirall Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/9/2026)
| Balance Sheet | Total Assets | 2,337,130,000.00 | ROE | 63.63 % |
| Balance Sheet | Total Equity | 1,487,130,000.00 | ROA | 1.98 % |
| Cashflow | Capital Expenditures | -34,910,000.00 | P/FCF | 16.31 |
| Cashflow | Free Cash Flow | 134,288,992.00 | – | – |
| Cashflow | Operating Cash Flow | 169,199,000.00 | P/CF | 12.95 |
| Income | Earnings per Share (diluted) | 0.22 | Div. Yield | – |
| Income | Net Income | 46,200,000.00 | P/E | 46.36 |
| Income | Shares Outstanding | 214,784,000.00 | P/B | 1.47 |
| Income | Total Revenue | 1,114,500,000.00 | P/S | 1.97 |
Ratios calculated on: 10/14/2026
Company Description
Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for the central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases; and Happify Health to develop evidence-supported digital therapeutics solutions for psoriasis patients. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.almirall.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more